XNAS · Healthcare · Biotechnology
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.23 | -0.29 | -26.09% | $0 | ❌ Miss | +1.32% | -5.08% | — |
| 2026-03-17 | Q4 2025 | -0.24 | -0.29 | -20.83% | $0 | ❌ Miss | -1.20% | -24.60% | -37.20% |
| 2025-11-12 |
| Q3 2025 |
| -0.22 |
| -0.31 |
| -40.91% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.31 | -0.21 | +32.26% | $0 | ✅ Beat | +1.90% | +9.52% | +20.95% |
| 2025-03-25 | Q4 2024 | -0.26 | -0.25 | +3.85% | $0 | ✅ Beat | +1.33% | -8.00% | -14.00% |
| 2024-11-13 | Q3 2024 | -0.54 | -0.43 | +20.37% | $0 | ✅ Beat | -0.99% | +28.71% | +41.58% |
| 2024-08-13 | Q2 2024 | -0.59 | -0.48 | +18.64% | $0 | ✅ Beat | -3.67% | -3.67% | -4.59% |
| 2024-05-14 | Q1 2024 | -0.62 | -0.56 | +9.68% | $0 | ✅ Beat | -1.73% | -6.28% | -13.85% |
Showing last 8 quarters.